# A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment

> **NCT01232296** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 162 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** dovitinib
- **DRUG:** sorafenib

## Key facts

- **NCT ID:** NCT01232296
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2015-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01232296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01232296, "A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01232296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*